Bromide

Bromide

SCHEMBL2979400

CCCCCCCCCCCCCCCCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1.[Br-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.56
TRAP1 Q12931 2/20 0.46
CHRNA7 P36544 7/20 0.45
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
DNM1 Q05193 2/20 0.43
CSNK1E P49674 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL286882 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL2446607 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL678415 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL362235 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL1866839 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL7759526 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL635580 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL8775234 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL164301 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2
Bromide SCHEMBL1963378 1.00 HIF1A (0.56) HIF1ATRAP1CHRNA7ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119411242-A Comfortable quick-response antibacterial and antiviral fiber and preparation method thereof 上海德福伦新材料科技有限公司 2025-02-11 CN claimed
CN-116948547-A Novel white reinforced photovoltaic backboard base film, preparation method and application thereof 宁波勤邦新材料科技股份有限公司 2023-10-27 CN claimed
CN-115536997-A Blending type barrier plastic packaging container 杭州恒峰塑料制品有限公司 2022-12-30 CN claimed
WO-2009002778-A1 ADDITIVES TO IMPROVE HIGH TEMPERATURE PERFORMANCE OF POLYESTERS ARKEMA INC. (US) 2008-12-31 WO claimed
EP-3710462-B1 BRARTEMICIN ANALOGUES VICTORIA LINK LTD (NZ) 2026-05-13 EP disclosed
US-12577264-B2 Borate compound-containing composition AGC Inc. (JP) 2026-03-17 US disclosed
CN-119411242-A Comfortable quick-response antibacterial and antiviral fiber and preparation method thereof 上海德福伦新材料科技有限公司 2025-02-11 CN disclosed
CN-116948547-B White reinforced photovoltaic backboard base film, preparation method and application thereof 宁波勤邦新材料科技股份有限公司 2024-09-17 CN disclosed
WO-2024105547-A1 6-C-LINKED TREHALOSE GLYCOLIPIDS VICTORIA LINK LIMITED (NZ) 2024-05-23 WO disclosed
EP-4274834-A1 ISOHEXANE-SOLUBLE UNSATURATED ALKYL ANILINIUM TETRAKIS(PERFLUOROARYL)BORATE ACTIVATORS ExxonMobil Chemical Patents Inc. (US) 2023-11-15 EP disclosed
CN-116948547-A Novel white reinforced photovoltaic backboard base film, preparation method and application thereof 宁波勤邦新材料科技股份有限公司 2023-10-27 CN disclosed
EP-4265623-A1 NOVEL BORATE COMPOUND AGC INC. (JP) 2023-10-25 EP disclosed
WO-2005047221-A1 PROCESS FOR THE PREPARATION OF ALIPHATIC PRIMARY ALCOHOLS AND INTERMEDIATES IN SUCH PROCESS DSM IP ASSETS B.V. (NL) 2005-05-26 WO disclosed
US-5446189-A Diester intermediates for diacid enzyme inhibitor HOFFMANN-LA ROCHE INC. (US) 1995-08-29 US disclosed
US-5324747-A Treatment of inflammatory diseases HOFFMANN-LA ROCHE INC. (US) 1994-06-28 US disclosed
EP-0579066-A2 N-substituted anilines F. HOFFMANN-LA ROCHE AG (CH) 1994-01-19 EP disclosed
EP-0109354-A1 Biocidally active mixture CIBA-GEIGY AG (CH) 1984-05-23 EP disclosed
EP-0097890-A2 Process for producing an aromatic polyester MITSUBISHI KASEI CORPORATION (JP) 1984-01-11 EP disclosed
US-4035346-A ANTISTATIC E. I. DU PONT DE NEMOURS AND CO. (US) 1977-07-12 US disclosed
US-4006123-A Conductive aliphatic polyester or polyetherester having units containing phosphonium sulfonate groups E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577264-B2 Borate compound-containing composition AFF1, RFC1, RFC3 HIF1A 2027/4885TRAP1 4691/4885CHRNA7 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.